Amgen Inc. Stock News

GW Henssler & Associates Ltd. boosted its stake in Amgen Inc. (NASDAQ:AMGN) by 8.7% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 86,217 shares of the medical research companys stock after acquiring an additional 6,898 shares during the quarter. GW []

TFC Financial Management boosted its position in shares of Amgen Inc. (NASDAQ:AMGN) by 8.5% during the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 635 shares of the medical research company’s stock after purchasing an additional 50 shares during the period. TFC Financial Management’s holdings […]

THOUSAND OAKS, Calif., Dec. 23, 2021 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 14th Annual Healthcare CEOs Unscripted Conference at 1:00 p.m.

Amgen Inc. (NASDAQ:AMGN) Investment analysts at Oppenheimer boosted their FY2025 earnings per share estimates for Amgen in a research report issued to clients and investors on Monday, December 20th. Oppenheimer analyst J. Olson now forecasts that the medical research company will post earnings per share of $23.19 for the year, up from their prior []

Clifford Swan Investment Counsel LLC lessened its position in shares of Amgen Inc. (NASDAQ:AMGN) by 0.8% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 46,351 shares of the medical research companys stock after selling 365 shares during the period. []

Magnolia Capital Management Ltd. acquired a new stake in shares of Amgen Inc. (NASDAQ:AMGN) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,100 shares of the medical research companys stock, valued at approximately $447,000. Other hedge funds and other institutional investors []

Renaissance Investment Group LLC lessened its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 13.7% in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 15,838 shares of the medical research companys stock after selling 2,509 shares during the period. Renaissance Investment Group LLCs holdings in Amgen were []

New York State Common Retirement Fund cut its holdings in Amgen Inc. (NASDAQ:AMGN) by 4.5% during the 3rd quarter, HoldingsChannel reports. The fund owned 1,102,368 shares of the medical research companys stock after selling 51,909 shares during the quarter. New York State Common Retirement Funds holdings in Amgen were worth $234,419,000 as of its most []

Amgen announced an investment of $100 million for the construction of a new vial filing line with ‘state of the art’ technology and new site infrastructure at its manufacturing plant in Dun Laoghaire, Co Dublin. This investment is one of Amgen’s largest construction projects outside North America and will lead to the creation of 150 […]

DUBLIN--(BUSINESS WIRE)--The "Global Pharmaceutical Drug Delivery Market by Route of Administration (Oral, Injectors, Implantable, Syrups, Gels, Pulmonary, Solutions, Tablets, Syringes), Application (Cancer, Diabetes), Facility of Use (Hospitals), COVID-19 Impact - Forecast to 2026" report has been added to ResearchAndMarkets.com''s offering. The global pharmaceutical drug delivery market is projected to reach USD 2,206.5 billion by 2026 from USD 1,656.9 billion in 2021, at a CAGR of 5.9% during

The drug is already approved for three indications, including to treat patients with moderate-to-severe plaque psoriasis and psoriatic arthritis The post US FDA approves expanded use of Amgens psoriasis drug appeared first on Express Pharma .

The FDA has approved Amgen Inc''s (NASDAQ: AMGN ) Otezla (apremilast) to treat adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy. With this expanded indication, Otezla is now the first and only oral treatment approved in … Full story available on Benzinga.com

The FDA has approved Amgen Inc's (NASDAQ: AMGN) Otezla (apremilast) to treat adult patients with plaque psoriasis who are candidates for phototherapy or systemic therapy.  With this expanded indic

Senti Biosciences Inc, the synthetic biology play helmed by MIT whiz Tim Lu, will be merging with Farokhzad's Dynamics Special Purpose Corp (NASDAQ: DYNS) in a deal set to deliver $296 million in g

Amgen (AMGN) and AstraZeneca's (AZN) Tezspire is the only biologic medicine approved by the FDA to treat severe asthma with no phenotype limitation and irrespective of biomarker levels.